[Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma and their significance in clinical settings].
OBJECTIVE
To identify serologic markers that may indicate the early presence of hepatocellular carcinoma (HCC), and analyze their significance in the pathogenesis of chronic hepatitis B.


METHODS
Hepatitis B x antigen (HBxAg) positive and negative HepG2 cells were subjected to PCR select cDNA subtraction to identify differentially expressed genes that may precede the development of HCC. These included the up-regulated genes URG4, URG7, URG11, and VEGFR3, and the down-regulated gene, Sui1. Specific ELISAs were constructed to measure differentially expressed antigens and their corresponding antibodies to determine whether they had prognostic and/or diagnostic value. The study population consisted of 730 people. Among them, 416 were HBsAg(-) and 298 were HBV carriers with chronic liver disease and/or HCC. In addition, 16 patients had non-viral hepatitis. Among these, serial serum samples from 53 HBsAg(+) patients with cirrhosis were collected and studied.


RESULTS
Antibodies to multiple differentially regulated genes were detectable in serum samples from patients with HBV associated cirrhosis and HCC, but not in serum samples from uninfected individuals (P < 0.01). Antibodies were undetectable in serum samples from HBV patients without liver disease and in serum samples from patients with other tumor types, and among those with non viral hepatitis. Among patients at high risk of developing HCC, these antibodies were found to be independent of nationality and ethnicity. Statistical analysis of the 28 HBsAg(+) patients with HCC showed that anti-URG11 and anti-VEGFR3 were the most frequently detected antibodies. These antibodies were found to coexist in 16 (P < 0.05). In contrast, among the 25 HBsAg(+) patients without HCC, anti-Sui1 and anti-URG7 were the most prevalent antibodies. These antibodies coexisted in 11 (P < 0.05). In addition, HCC patients with four or more antibodies detected before the appearance of HCC had a poorer survival outcome.


CONCLUSIONS
These antibodies can be detected in serum samples several months to several years before the appearance of HCC. This suggests that they may be preneoplastic markers that may help to distinguish which HBV carriers with cirrhosis are most likely to progress and develop HCC.
Tong
Guang-Dong
GD
Department of Liver Diseases, Affiliated Shenzhen Traditional Chinese Medicine Hospital, Guangzhou University of Traditional Chinese Medicine, Shenzhen 518033, China.
Zhou
Da-Qiao
DQ
He
Jin-Song
JS
Xiao
Chun-Ling
CL
Liu
Xin-Liang
XL
Zhou
Xiao-Zhou
XZ
Zhang
Xi
X
Xing
Yu-Feng
YF
Lü
Ping
P
Feitelson
Mark A
MA
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D014408:Biomarkers, Tumor; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis* / Q000821:virology; D005260:Female; D056945:Hep G2 Cells; D006508:Hepatitis Antibodies / Q000097:blood*; D006515:Hepatitis B virus; D019694:Hepatitis B, Chronic / Q000097:blood* / Q000150:complications; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000821:virology; D008297:Male; D008875:Middle Aged; D011230:Precancerous Conditions; D011379:Prognosis; D055815:Young Adult
D015415:Biomarkers; D014408:Biomarkers, Tumor; D006508:Hepatitis Antibodies